- Details
- Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...
|
- Details
- Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...
|
- Details
- Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...
|
- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- Alicia Morgans engages with Fred Saad to discuss a network meta-analysis concerning treatments for patients with metastatic hormone-sensitive prostate cancer. They explore the controversies surrounding the most effective treatment for newly diagnosed disease, considering factors like disease volume and whether it's recurrent or de novo. Dr. Saad explains the diminishing role of ADT alone, emphasiz...
|
- Details
- Alicia Morgans interviews Ben Maughan focusing on a published network meta-analysis involving 11 randomized control trials for patients treated for metastatic hormone-sensitive prostate cancer. The analysis stirred significant debate on Twitter and sought to establish whether triplet therapy was superior to other approaches like ADT plus docetaxel and ADT plus an AR-targeted therapy. Dr. Maughan e...
|
- Details
- In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....
|
- Details
- Karim Fizazi discusses the substantial progress made in treating metastatic castration-sensitive prostate cancer. In their conversation, Dr. Fizazi emphasizes the importance of understanding different patient scenarios based on volume and the timing of the metastasis, highlighting the distinctions between de novo metastatic disease and relapse after local treatment. He breaks down four scenarios t...
|
- Details
- At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022: Treatment...
|
- Details
- Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...
|
